Scotia Capital Inc. boosted its position in The Valens Company Inc. (NASDAQ:VLNS – Get Rating) by 418.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 53,095 shares of the company's stock after purchasing an additional 42,856 shares during the quarter. Scotia Capital Inc.'s holdings in Valens were worth $33,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its stake in Valens by 144.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 32,019 shares of the company's stock valued at $55,000 after purchasing an additional 18,932 shares during the period. CoreCap Advisors LLC boosted its stake in Valens by 205.7% in the 1st quarter. CoreCap Advisors LLC now owns 41,269 shares of the company's stock valued at $71,000 after purchasing an additional 27,770 shares during the period. Jane Street Group LLC boosted its stake in Valens by 76.1% in the 1st quarter. Jane Street Group LLC now owns 55,585 shares of the company's stock valued at $94,000 after purchasing an additional 24,012 shares during the period. Commonwealth Equity Services LLC boosted its stake in Valens by 26.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 174,601 shares of the company's stock valued at $113,000 after purchasing an additional 36,749 shares during the period. Finally, Empery Asset Management LP bought a new stake in Valens in the 1st quarter valued at $688,000. 5.04% of the stock is currently owned by institutional investors.
Get Valens alerts:Valens Price Performance
Shares of NASDAQ VLNS opened at $0.69 on Thursday. The company has a quick ratio of 1.49, a current ratio of 2.08 and a debt-to-equity ratio of 0.80. The Valens Company Inc. has a fifty-two week low of $0.58 and a fifty-two week high of $4.89. The business has a fifty day moving average price of $0.74 and a two-hundred day moving average price of $0.78.
Analyst Upgrades and Downgrades
VLNS has been the subject of several recent research reports. Stifel Nicolaus reduced their price target on Valens from C$3.50 to C$1.20 in a research note on Tuesday, August 23rd. Canaccord Genuity Group dropped their price objective on Valens from C$6.75 to C$4.00 in a report on Friday, July 15th. Atb Cap Markets cut Valens from an "outperform" rating to a "sector perform" rating in a report on Thursday, July 14th. Finally, Raymond James dropped their price objective on Valens from C$2.50 to C$1.00 in a report on Wednesday, July 20th.Valens Company Profile
(Get Rating)
The Valens Company Inc, through its subsidiaries, develops, manufactures, and sells cannabinoid-based products in Canada, the United States, and internationally. The company provides packaged dried flower/pre-rolls under the Verse, Versus, Contraband, and Citizen Stash brands; vapourizers and hydrocarbon extracts under the Verse and Versus brands; edible cannabis products under the Verse, Vacay, and LYF brands; and topical cannabis under the Nuance brand.
Further Reading
- Get a free copy of the StockNews.com research report on Valens (VLNS)
- Is Triple-Digit Growth Ahead For Digital Ad Platform Trade Desk?
- EV Maker Lucid Falls On Declining Orders, Rivian Up On Guidance
- DoorDash Outperforms Despite Losses – Is It Time To Buy?
- Analysts Rate DraftKings a Moderate Buy As Growth Slows
- Goodyear Tire & Rubber Stock is Becoming a Mighty Good Bargain
Want to see what other hedge funds are holding VLNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Valens Company Inc. (NASDAQ:VLNS – Get Rating).
Receive News & Ratings for Valens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valens and related companies with MarketBeat.com's FREE daily email newsletter.